Why the study?
Does treatment of malignant hypertension improve markers of endothelial dysfunction, platelet activation, and thrombogenesis?
Does treatment of malignant hypertension improve markers of endothelial dysfunction, platelet activation, and thrombogenesis?
Malignant hypertension is associated with endothelial dysfunction and abnormal hemorheology, which are partially reversed by 6 months of treatment.
Answers are grounded in this paper and cite their sources.
MHT treatment may partially improve endothelial and platelet markers; hypothesis-generating and should not yet change practice.
Hypertension is associated with thrombotic complications. We hypothesised that the most severe form of hypertension, malignant hypertension (MHT) is associated with disturbances of endothelial function, platelet activation and thrombogenesis and that treatment improves these parameters. To investigate this further we compared 18 patients presenting with MHT (15 male; mean age 48 ± 11) to 18 healthy controls. von Willebrand factor (vWf, a marker of endothelial dysfunction), soluble P-selectin (sPsel, a marker of platelet activation) (both ELISA) and fibrinogen (Fib, a marker of clotting and haemorheology) (Clauss) were measured in patients at presentation and after 6 months treatment. (See Table) Baseline vs control: p = 0.0064, p = 0.0001. MHT baseline vs after treatment: p = 0.034, p = 0.0035. Baseline vs control: p = 0.0064, p = 0.0001. MHT baseline vs after treatment: p = 0.034, p = 0.0035. In conclusion, patients presenting with MHT demonstrate endothelial damage/dysfunction (vWf) and abnormal haemorheology (fibrinogen). vWf and sPsel but not fibrinogen are reduced by treatment. These abnormalities may contribute to the pathogenesis of MHT and its complications.
No takes yet. Share an insight, caveat, or question.
Eiry Edmunds (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: